

JFW

PTO/SB/21 (09-04)  
Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number	10/691,079
Filing Date	October 22, 2003
First Named Inventor	Luc MERCKEN et al.
Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	FRAV2002/0030 US NP

### ENCLOSURES (Check all that apply)

- |   |  |  |
|---|--|--|
| <input type="checkbox"/> Fee Transmittal Form<br><input type="checkbox"/> Fee Attached<br><input type="checkbox"/> Amendment/Reply<br><input type="checkbox"/> After Final<br><input type="checkbox"/> Affidavits/declaration(s)<br><input type="checkbox"/> Extension of Time Request<br><input type="checkbox"/> Express Abandonment Request<br><input checked="" type="checkbox"/> Information Disclosure Statement<br><br><input type="checkbox"/> Certified Copy of Priority Document(s)<br><input type="checkbox"/> Reply to Missing Parts/<br>Incomplete Application<br><input type="checkbox"/> Reply to Missing Parts<br>under 37 CFR 1.52 or 1.53 | <input type="checkbox"/> Drawing(s)<br><input type="checkbox"/> Licensing-related Papers<br><input type="checkbox"/> Petition<br><input type="checkbox"/> Petition to Convert to a<br>Provisional Application<br><input type="checkbox"/> Power of Attorney, Revocation<br>Change of Correspondence Address<br><input type="checkbox"/> Terminal Disclaimer<br><input type="checkbox"/> Request for Refund<br><input type="checkbox"/> CD, Number of CD(s) _____<br><input type="checkbox"/> Landscape Table on CD | <input type="checkbox"/> After Allowance Communication to TC<br><input type="checkbox"/> Appeal Communication to Board<br>of Appeals and Interferences<br><input type="checkbox"/> Appeal Communication to TC<br>(Appeal Notice, Brief, Reply Brief)<br><input type="checkbox"/> Proprietary Information<br><input type="checkbox"/> Status Letter<br><input checked="" type="checkbox"/> Other Enclosure(s) (please identify<br>below):<br><div>Form 1449 - 4 pages<br/>27 references</div> |
|---|--|--|

Remarks

### SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT


Firm Name	AVENTIS PHARMACEUTICALS INC.		
Signature			
Printed name	Karen I. Krupen <i>Karen Krupen</i>		
Date	October 11, 2004	Reg. No.	34,647

### CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: (USPTO FAX NO. \_\_\_\_\_; Total No. of Pages Transmitted: \_\_\_\_\_)

Signature	<i>Delia Coughlin</i>		
Typed or printed name	Delia Coughlin	Date	10/12/04

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of  
**Mercken et al.**

Examiner: **Unknown**

Art Unit: **1614**

Application No.: **10/691,079**

Filed: **October 22, 2003**

Title: **INHIBITORS OF SRC KINASE FOR USE IN  
ALZHEIMER'S DISEASE**

I hereby certify that this correspondence is being  
deposited with the United States Postal Service as First  
Class Mail in an envelope addressed to Commissioner  
for Patents, P.O. Box 1450, Alexandria, VA 22313-  
1450, on

October 12, 2004  
Date of Deposit

Delia Anglin  
Signature

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 C.F.R. 1.56, 1.97 AND 1.98**

Mail Stop  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

- ☒ (a) This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. **18-1982**.

- ☒ (b) This Information Disclosure Statement is filed after the period set forth in 37 C.F.R. 1.97(b), but is believed to be filed before the mailing date of a final action under §1.113 or a notice of allowance under §1.311, whichever occurs first.
- ☐ (1) The undersigned attorney certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement;
- ☐ (2) The undersigned attorney certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned attorney after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this statement; or
- ☐ (3) This Information Disclosure Statement is accompanied by a transmittal letter in which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is authorized.

Respectfully submitted,



Karen I. Krupen, Reg. No. 34,647  
Attorney for Applicant

Aventis Pharmaceuticals Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, NJ 08807-0800  
Telephone (908) 231-4658  
Telefax (908) 231-2626  
Aventis Docket No. FRAV2002/0030USNP

☒

+

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

**Complete if Known**

<b>Application Number</b>	10/691,079
<b>Filing Date</b>	10-22-2003
<b>First Named Inventor</b>	MERCKEN
Group Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	FRAV2002/0030 - US - NP

[illegible][illegible]

Examiner  
Signature

Date	
Considered	

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box → ☒

PTO/SB/08B (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>	
			<b>Application Number</b>	10/691,079
			<b>Filing Date</b>	10-22-2003
			<b>First Named Inventor</b>	MERCKEN
			<b>Group Art Unit</b>	1614
			<b>Examiner Name</b>	Unknown
			<b>Attorney Docket Number</b>	FRAV2002/0030 - US - NP
<b>Sheet</b>	2	<b>of</b>	4	

<b>OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS</b>			
<b>Examiner Initials*</b>	<b>Cite No.<sup>1</sup></b>	<b>Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.</b>	<b>T<sup>2</sup></b>
		A.E. APLIN et al., In Vitro Phosphorylation of the Cytoplasmic Domain of the Amyloid Precursor Protein by Glycogen Synthase Kinase-3 Beta, Journal of Neurochemistry, Vol. 67, 1996, pp. 699-707	
		B. SLACK, A Role for SRC Tyrosine In the Stimulation of Amyloid Precursor Protein Release by Activation of Muscarinic m3 Acetylcholine Receptors, Society for Neuroscience, Vol. 28, 1998, Abstract	
		C.L. STANDEN et al., Phosphorylation of thr668 in the cytoplasmic domain of the Alzheimer's disease amyloid precursor protein by stress-activated protein kinase, Journal of Neurochemistry, Vol. 76, 2001, pp. 316-320	
		D. SCHEUNER et al., Secreted amyloid B-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease, Nature Medicine 2(8), 864-870 (1996)	
		HILBICH, Caroline et al., Aggregation and Secondary Structure Of Synthetic Amyloid BetaA4 Peptides of Alzheimer's Disease, J. Mol. Biol. Vol. 218, 1991, pp. 149-163	
		J. BORG et al., The X11 alpha Protein Slows Cellular Amyloid Precursor Protein Processing and Reduces A beta 40 and A beta 42 Secretion, Journal of Biological Chemistry, Vol. 273, No. 24, June 12, 1998, pp. 14761-14766	
		J. KANG et al., The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor, Nature, (1987), Vol. 325, Feb. 198 pp. 733 - 736	
		J.H. HANKE et al., Discovery of a Novel, Potent, and Src Family-selective Tyrosine Kinase Inhibitor, Journal of Biological Chemistry, Vol. 271, Jan. 12, 1996, pp. 695-701	
		K. ANDO et al., Phosphorylation-dependent Regulation of the Interaction of Amyloid Precursor Protein with Fe65 Affects the Production of Beta-Amyloid, Journal of Biological Chemistry, Vol. 276, No. 43, Oct. 26, 2001, pp. 40353-40361	
		K. ANDO et al., Role of Phosphorylation of Alzheimer's Amyloid Precursor Protein during Neuronal Differentiation, Journal of Neuroscience, Vol. 19, No. 11, June 1, 1999, pp. 4421-4427	

<b>Examiner Signature</b>		<b>Date Considered</b>	
-------------------------------	--	----------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☒

PTO/SB/08B (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>			<b>Complete if Known</b>		
			Application Number	10/691,079	
			Filing Date	10-22-2003	
			First Named Inventor	MERCKEN	
			Group Art Unit	1614	
			Examiner Name	Unknown	
Sheet	3	of	4	Attorney Docket Number	FRAV2002/0030 - US - NP

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		K. BONHAM et al., An Alternative, Human SRC Promoter and Its Regulation by Hepatic Nuclear Factor-1alpha, Journal of Biological Chemistry, Vol. 275, No. 48, Dec. 1, 2000, pp. 37604-37611	
		K. IJIMA et al., Neuron-Specific Phosphorylation of Alzheimer's Beta-Amyloid Precursor Protein by Cyclin-Dependent Kinase 5, Journal of Neurochemistry, Vol. 75, 2000, pp. 1085-1091	
		KIHARA Takeshi et al., Alpha-7 Nicotinic Receptor Transduces Signals To Phosphatidylinositol 3-Kinase To Block A Beta-Amyloid-Induced Neurotoxicity, The Journal Of Biological Chemistry, (2001), Vol. 276, No. 17, pp. 13541 - 13546	
		M. OISHI et al., The Cytoplasmic Domain of Alzheimer's Amyloid Precursor Protein Is Phosphorylated at Thr654, Ser655, and Thr668 in Adult Rat Brain and Cultured Cells, Molecular Medicine, Vol. 3, No. 2, Feb. 1997, pp. 111-123	
		M. SIMONS et al., Amyloidogenic Processing of the Human Amyloid Precursor Protein in Primary Cultures of Rat Hippocampal Neurons, Journal of Neuroscience, Vol. 16, No 3, Feb. 1, 1996, pp. 899-908	
		MARUYAMA, Kei et al., Cleavage At The N-Terminal Site Of Alzheimer Amyloid Beta/Alpha 4 Protein Is Essential For Its Secretion, Biochemical and Biophysical Research Communications, Aug. 14, 1994, Vol. 202, No. 3, pp. 1517 - 1523	
		RUMBLE, Baden et al., Amyloid A4 Protein and its Precursor In Downs Syndrome and Alzheimer's Disease, The New England Journal of Medicine, Vol. 320, No. 22, June 1, 1989, pp. 1446 - 1452	
		S. ESTUS et al., Potentially Amyloidogenic, Carboxyl-Terminal Derivatives of the Amyloid Protein Precursor, Science, (Vol. 255), 1992, pp. 726 - 728	
		S.L. SABO et al., Regulation of Beta-Amyloid Secretion by FE65, an Amyloid Protein Precursor-binding Protein, Journal of Biological Chemistry, Vol. 274, No. 12, March 19, 1999, pp. 7952-7957	
		B.A. YANKNER et al., Nerve growth factor potentiates the neurotoxicity of Beta amyloid, Proc. Natl. Acad. Sci, USA, Vol. 87, Nov. 1990, pp. 9020-9023	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☒

PTO/SB/08B (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/691,079	
			Filing Date	10-22-2003	
			First Named Inventor	MERCKEN	
			Group Art Unit	1614	
			Examiner Name	Unknown	
Sheet	4	of	4	Attorney Docket Number	FRAV2002/0030 - US - NP

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>*</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		T. RUSSO et al., Fe65 and the protein network centered around the cytosolic domain of the Alzheimer's Beta-amyloid precursor protein, FEBS Letters, Vol. 434, 1998, pp. 1-7	
		T. SUZUKI et al., Cell cycle-dependent regulation of the phosphorylation and metabolism of the Alzheimer amyloid precursor protein, EMBO Journal, Vol. 13, 1994, pp. 1114-1122	
		T.E. KMIECIK et al., Activation and Suppression of pp60c-src Transforming Ability by Mutation of Its Primary Sites of Tyrosine Phosphorylation, Cell, Vol. 29, 1987, pp. 65-73	
		WILLIAMSON Ritchie et al., Rapid Tyrosine Phosphorylation Of Neuronal Proteins Including Tau And Focal Adhesion Kinase In Response To Amyloid-Beta Peptide Exposure: Involvement Of SRC Family Protein Kinases, The Journal Of Neuroscience, (2002), Vol. 22, No. 1, pp. 10 - 20	
		Zambrano et al., Interaction of the Phosphotyrosine Interaction/Phosphotyrosine Binding-related Domains of Fe65 with Wild-type Mutant Alzheimer's B-Amyloid Precursor Proteins, Journal of Biological Chemistry 272 (10), 6399-6405 (1997)	
		N. ZAMBRANO et al., The Beta-Amyloid Precursor Protein APP is Tyrosine-phosphorylated in Cells Expressing a Constitutively Active Form of the Abl Protooncogene, Journal of Biological Chemistry, Vol. 276, No. 23, June 8, 2001, pp. 19787-19792	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.